Veterinary Drug terms — page 4 | HESTIA Glossary

Browse all 1,061 veterinary drug terms HESTIA uses to describe agricultural data — with definitions and synonyms. Free and open.

Aminolevulinic acid D-Aminolevulinic acid; Aminolevulinic acid; Aminolevulinic acid
Aminooxyacetic acid 2-(Aminooxy)acetic acid; Aminooxyacetic acid; U 7524
Aminopterin N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid; Aminopterin; 4-26-00-03831 (Beilstein Handbook Reference)
Aminopyrine 4-(Dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl-3H-pyrazol-3-one; AMINOPYRINE; aminophenazone; Amidopyrine; 58-15-1; 4-Dimethylaminoantipyrine; Dipyrine; Aminofenazone; Amidazophen; Amidophen; Aminopyrin; Pyramidon; Dimethylaminoazophene; Dimethylaminophenazone; Amidophenazone; Amidopyrazoline; Aminophenazon; Dimethylaminoantipyrine; Amidazophene; Amidofebrin; Amidofen; Amidopyrin; Anafebrina; Eufibron; Pyramidone; Amidazofen; Brufaneuxol; Piromidina; Dereuma; Dimapyrin; Dipirin; Dipyrin; Febrinina; Hyparon; Itamidone; Novamidon; Piramidon; Pirazon; Piridol; Polinalin; Pyradone; Febron; 4-(Dimethylamino)antipyrine; Mamallet-A; 4-Dimethylaminophenazone; Netsusarin; Dimethylamino-analgesine; 4-Dimethylamino-2,3-dimethyl-1-phenyl-3-pyrazolin-5-one; Dimethylaminophenyldimethylpyrazolone; Dimethylaminophenazon; Amidazophenum; Amidopyrinum; Aminofenazona; Aminophenazonum; Aminopyrinum; (Dimethylamino)phenazone; 4-(Dimethylamino)-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one; Antipyrine, 4-(dimethylamino)-; 4-Dimethylamino-1-phenyl-2,3-dimethylpyrazolone; 1,5-Dimethyl-4-dimethylamino-2-phenyl-3-pyrazolone; 1-Phenyl-2,3-dimethyl-4-dimethylaminopyrazol-5-one; 2,3-Dimethyl-4-dimethylamino-1-phenyl-5-pyrazolone; 4-Dimethylamino-2,3-dimethyl-1-phenyl-5-pyrazolone; Aminophenazon [German]; Aminofenazone [Italian]; 3H-Pyrazol-3-one, 4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl-; Dimethylaminophenyldimethylpyrazolin; Aminofenazona [INN-Spanish]; Aminophenazonum [INN-Latin]; Aminopyrine [JAN]; Dimethylaminophenazon [German]; UNII-01704YP3MO; CCRIS 2907; 3-Keto-1,5-dimethyl-4-dimethylamino-2-phenyl-2,3-dihydropyrazole; HSDB 2135; NSC 4993; EINECS 200-365-8; MFCD00003142; 4-(Dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl-3H-pyrazol-3-one; 1-Phenyl-2,3-dimethyl-4-(dimethylamino)-5-pyrazolone; 4-(dimethylamino)-1,5-dimethyl-2-phenylpyrazol-3-one; MLS002154195; 3-Pyrazolin-5-one, 4-(dimethylamino)-2,3-dimethyl-1-phenyl-; C13H17N3O; CHEBI:160246; RMMXTBMQSGEXHJ-UHFFFAOYSA-N; 01704YP3MO; Aminopyrine (JAN); Aminophenazone (INN); Aminophenazone [INN]; CAS-58-15-1; NCGC00016257-04; SMR001216566; DSSTox_CID_504; 4,4-Dimethylaminophenazone; DSSTox_RID_75627; DSSTox_GSID_20504; 1-Phenyl-2,3-dimethyl-4-dimethylaminopyrazolone-5; 4-Dimethylaminoantipyrine, 97%; Amidophenazon; 4-(dimethylamino)-2,3-dimethyl-1-phenyl-3-pyrazolin-5-one; Aminopyrine [JAN:NF]; SR-05000001741; Dimethyl-N-aminoantipyrine; Piramidone; Dimethylaminophenyldimethylpyrazone; Prestwick_14; dimethylaminoanalgesine; Prestwick0_000088; Prestwick1_000088; Prestwick2_000088; Prestwick3_000088; 4-(Dimethylamino)phenazone; cid_6009; TimTec1_000737; 3-keto-1,3-dihydropyrazole; Oprea1_080671; SCHEMBL26293; BSPBio_000016; 4-N,N-Dimethylaminoantipyrine; ARONIS24560; SPBio_001955; BPBio1_000018; CHEMBL288470; 4-(dimethylamino)-1,5-dimethyl-2-phenyl-pyrazol-3-one; DTXSID7020504; BDBM74258; ZINC57115; BBC/732; NSC4993; HMS1536B11; HMS1568A18; HMS2092E10; HMS2095A18; HMS3039C06; HMS3652G13; HMS3712A18; Pharmakon1600-01500621; HY-B0533; NSC-4993; ZX-AS004932; dimethylamino phenyldimethylpyrazolone; Tox21_110333; Tox21_201544; Tox21_302830; LS-239; NSC757388; s3209; STL356033; AKOS001590378; Tox21_110333_1; CCG-103785; CS-2627; DB01424; MCULE-1554715918; NSC-757388; KS-0000477V; NCGC00016257-01; NCGC00016257-02; NCGC00016257-03; NCGC00016257-05; NCGC00016257-06; NCGC00016257-07; NCGC00016257-10; NCGC00090878-01; NCGC00090878-02; NCGC00090878-03; NCGC00175173-01; NCGC00175173-02; NCGC00256436-01; NCGC00259094-01; 3-Pyrazolin-5-one,3-dimethyl-1-phenyl-; AC-12025; CC-24081; ST011911; SBI-0207073.P001; WLN: T5NNVJ A1 BR& DN1&1 E1; AB1009251; DB-053161; TR-020242; B1883; FT-0622298; SW196332-3; Aminophenazone 100 microg/mL in Acetonitrile; A11805; C07539; D00556; C-29864; Q416503; 1,5-Dimethyl-2-phenyl-4-dimethylamino-3-pyrazolone; SR-05000001741-1; SR-05000001741-3; SR-05000001741-4; 4-(dimethylamino)-1,5-dimethyl-2-phenyl-3-pyrazolone; BRD-K12568846-001-04-7; 4-(dimethylamino)-1,5-dimethyl-2-phenyl-3-pyrazolin-3-one; 4-Dimethylaminoantipyrine, reactive nitrogen species scavenger; 3-keto-1,5-dimethyl-4-dimethylamino-2-phenyl -2,3-dihydropyrazole; 4-(dimethylamino)-1,5-dimethyl-2-phenyl-1H-pyrazol-3(2H)-one; 4-(Dimethylamino)-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one #; 4-(dimethylamino)-1,5-dimethyl-2-phenyl-2,3-dihydro-1H-pyrazol-3-one; 4-Dimethylamino-2,3-dimethyl-1-phenyl-3-pyrazolin-5-one; Aminopyrine; Aminophenazone (4-Dimethylamino-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one); 4-Dimethylamino-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one (4,4-Dimethylaminophenazone); Aminopyrine; Amidazofen
Aminosalicylic Acid 4-Aminosalicylic acid; p-Aminosalicylic acid; A 1909
Amitriptyline 3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine; Amitriptyline; Amitriptylin; Elavil; 50-48-6; Damitriptyline; Triptanol; Damilen; Lantron; Seroten; Flavyl; Proheptadiene; Adepress; Triptisol; Tryptanol; Adepril; Amitriprolidine; Amitryptiline; Triptilin; Redomex; Amytriptylin; Damilan; Ro 4-1575; Amitriptylin [German]; Amitriptilina [Italian]; Amitriptyline [INN:BAN]; Amitril; Sarotex; Amitriptylinum [INN-Latin]; Amitriptilina [INN-Spanish]; MK 230; 5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene; 10,11-Dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo(a,d)cycloheptene; 3-(10,11-Dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine; 3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethylpropan-1-amine; CCRIS 9174; UNII-1806D8D52K; HSDB 3007; N 750; EINECS 200-041-6; CHEMBL629; 5-(3'-Dimethylaminopropylidene)-dibenzo-(a,d)(1,4)-cycloheptadiene; BRN 2217885; 3-(10,11-Dihydro-5H-dibenzo(a,d)cyclohepten-5-yliden)-N,N-dimethylpropylamin; 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-; CHEBI:2666; KRMDCWKBEZIMAB-UHFFFAOYSA-N; 5-(gamma-Dimethylaminopropylidene)-5H-Dibenzo[a,d][1,4]cycloheptadiene; 5-(gamma-Dimethylaminopropylidine)-5H-dibenzo(a,d)(1,4)cycloheptadiene; Limbitrol; 5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptatriene; 5-(gamma-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene; 10,11-Dihydro-N,N-dimethyl-5H-dibenzo(a,d)heptalene-delta(sup 5),gamma-propylamine; 1806D8D52K; Amitriptilina; Amitriptylinum; Amitryptyline; Amytriptiline; Laroxil; Elanil; 10,11-Dihydro-N,N-dimethyl-5H-dibenzo(a,d)heptalene-delta(5),gamma-propylamine; 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl-; 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethylpropan-1-amine; 5H-Dibenzo(a,d)cycloheptene-delta5,gamma-propylamine, 10,11-dihydro-N,N-dimethyl-; W-109252; 5-(3'-Dimethylaminopropylidene)-dibenzo-[a,d][1,4]-cycloheptadiene; 10,11-dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo[a,d]cycloheptene; 5-(gamma-Dimethylaminopropylidene)-5H-dibenzo(a,d)(1,4)cycloheptadiene; 3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine; 5H-Dibenzo(a,d)cycloheptene-delta(sup 5),gamma-propylamine, 10,11-dihydro-N,N-dimethyl-; 5H-Dibenzo[a,d]cycloheptene-.delta.5,.gamma.-propylamine, 10,11-dihydro-N,N-dimethyl-; Laroxyl (TN); Amitriptyline (INN); NSC169910; NCGC00015095-09; CAS-549-18-8; Domical (Salt/Mix); Laroxyl (Salt/Mix); Lentizol (Salt/Mix); Vanatrip (Salt/Mix); Triptizol (Salt/Mix); Spectrum_000044; Prestwick0_000074; Prestwick1_000074; Prestwick2_000074; Prestwick3_000074; Spectrum2_000101; Spectrum3_000298; Spectrum4_000146; Spectrum5_000806; Lopac-A-8404; EC 200-041-6; SCHEMBL7824; Lopac0_000112; Oprea1_479304; BSPBio_000287; BSPBio_001836; GTPL200; KBioGR_000592; KBioGR_002261; KBioSS_000424; KBioSS_002262; ARONIS24381; BIDD:GT0115; DivK1c_000766; SPBio_000082; SPBio_002208; BPBio1_000317; DTXSID7022594; KBio1_000766; KBio2_000424; KBio2_002261; KBio2_002992; KBio2_004829; KBio2_005560; KBio2_007397; KBio3_001336; KBio3_002741; BBC/541; cMAP_000001; NINDS_000766; ZINC968257; 5-(3-dimethylaminopropylidene)dibenzo[a,d][1,4]-cycloheptadiene; BCP09083; ZX-AS004743; BBL028529; BDBM50020712; PDSP1_001564; PDSP2_001548; s5947; SBB080793; STK525215; 5-(3-Dimethylaminopropylidene)-5H-dibenzo[a,d]-10,11-dihydrocycloheptene; 5-(gamma-Dimethylaminopropylidene)-5H-dibenzo[a,d]10,11-dihydrocycloheptene; AKOS000512694; API0001457; CCG-204207; DB00321; MCULE-3537115467; SDCCGSBI-0050100.P005; 3-(10,11-Dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethyl-1-propanamine; IDI1_000766; MRF-0000533; NCGC00015095-01; NCGC00015095-02; NCGC00015095-03; NCGC00015095-04; NCGC00015095-05; NCGC00015095-06; NCGC00015095-07; NCGC00015095-08; NCGC00015095-10; NCGC00015095-11; NCGC00015095-12; NCGC00024433-04; NCGC00183047-01; dimethyl({3-[(2Z)-tricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-ylidene]propyl})amine; LS-60747; N,N-dimethyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylidene)propan-1-amine; SBI-0050100.P004; AB00514631; FT-0653242; 1409-EP2269989A1; 1409-EP2275420A1; 1409-EP2277861A1; 1409-EP2298313A1; 1409-EP2298731A1; 1409-EP2298764A1; 1409-EP2298765A1; 1409-EP2305652A2; 1409-EP2305669A1; 1409-EP2314585A1; C06824; D07448; Q58397; AB00053417-12; AB00053417_13; AB00053417_14; 412A072; L001041; BRD-K53737926-003-05-4; BRD-K53737926-003-14-6; (3-(5,6-dihydrodibenzo[b,f][7]annulen-11-ylidene)propyl)dimethylamine; 5-(.gamma.-Dimethylaminopropylidene)-5H-Dibenzo[a,d][1,4]cycloheptadiene; 5-(.gamma.-Dimethylaminopropylidine)-5H-dibenzo(a,d)(1,4)cycloheptadiene; 10,11-Dihydro-5-(.gamma.-dimethylaminopropylidene)-5H-dibenzo(a,d)cycloheptene; 10,11-dihydro-N,N-dimethl-5H-dibenzo[a,d]cycloheptene-(delta(5, gamma))-propylamine; 10,11-Dihydro-N,N-dimethyl-5H-dibenzo(a,d)heptalene-.DELTA.5,.gamma.-propylamine; 10,11-Dihydro-N,N-dimethyl-5H-dibenzo(a,d)heptalene-delta5,gamma-propylamine; 3-(5,6-dihydrodibenzo[[?],[?]][7]annulen-11-ylidene)-N,N-dimethyl-propan-1-amine; 5-(.gamma.-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene; 5-(.gamma.-Dimethylaminopropylidene)-5H-dibenzo(a,d)-10,11-dihydrocycloheptene; 3-(10,11-Dihydro-5H-dibenzo-[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine, hydrochloride; 5H-Dibenzo(a,d)cycloheptene-.delta.(sup 5),.gamma.-propylamine, 10,11-dihydro-N,N-dimethyl-; 5H-Dibenzo[a,d]cycloheptene-Delta5,gamma-propylamine, 10,11-dihydro-N,N-dimethyl- (6CI,8CI) 5-(gamma-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene; dimethyl({3-[(2E)-tricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3,5,7,11,13-hexaen-2-ylidene]propyl})amine; Amitriptyline; N 750
Amobarbital amobarbital; Amylobarbitone; Barbamyl; Barbamil; Pentymal; Amytal; Amobarbitone; Amylbarbitone; Amylobarbital; Eunoctal; Isomytal; Talamo; Barbamyl acid; 57-43-2; Binoctal; Dorlotyn; Dormytal; Mylodorm; Pentymalum; Schiwanox; Sednotic; Stadadorm; Amasust; Amital; Amospan; Amybal; Robarb; Somnal; Sumital; Isomyl; AMAL; Isoamylethylbarbituric acid; Ethylisopentylbarbituric acid; 5-Ethyl-5-isoamylbarbituric acid; 5-Ethyl-5-isopentylbarbituric acid; 5-Ethyl-5-isoamylmalonyl urea; 5-Ethyl-5-(3-methylbutyl)barbituric acid; 5-Isoamyl-5-ethylbarbituric acid; Amobarbitale [DCIT]; Barbituric acid, 5-ethyl-5-isopentyl-; Amobarbitalum [INN-Latin]; NSC 10815; 5-Ethyl-5-isopentylbarbitursaeure; UNII-GWH6IJ239E; 5-Ethyl-5-(3-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-(3-methylbutyl)-; 5-ethyl-5-(3-methylbutyl)-1,3-diazinane-2,4,6-trione; component of Dexamyl; component of Q-Caps; CCRIS 5454; HSDB 3286; component of 15-90; Amobarbital suppository dosage form; EINECS 200-330-7; component of Amo-Dextrosule; GWH6IJ239E; CHEBI:2673; 5-ethyl-5-(3-methylbutyl)pyrimidine-2,4,6(1H,3H,5H)-trione; NCGC00247711-01; Amobarbitale; Amobarbitalum; Amobarbital [INN:JAN]; DEA No. 2125; WLN: T6VMVMV FHJ F2 F2Y1&1; Isomytal (TN); 2,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-(3-methylbutyl)-; 5-Ethyl-5-(3-methylbutyl)-2,6(1H,3H,5H)-pyrimidinetrione; Amobarbital [USP:INN:BAN:JAN]; Dexamyl (Salt/Mix); DSSTox_CID_81; Amobarbital (JP17/INN); DSSTox_RID_75353; BIDD:PXR0091; DSSTox_GSID_20081; Oprea1_587446; SCHEMBL43780; CBDivE_006514; DivK1c_000994; CHEMBL267894; DTXSID9020081; SCHEMBL15364946; component of Dexamyl (Salt/Mix); KBio1_000994; VIROVYVQCGLCII-UHFFFAOYSA-; component of Q-Caps (Salt/Mix); NINDS_000994; VIROVYVQCGLCII-UHFFFAOYSA-N; component of 15-90 (Salt/Mix); Amobarbital 0.1 mg/ml in Methanol; Amobarbital 1.0 mg/ml in Methanol; NSC10815; NSC32406; ZINC4811698; Tox21_112866; NSC-10815; NSC-32406; NSC120800; Barbituric acid, 5-ethyl-5-isoamyl-; API0001485; DB01351; LS-7196; NSC-120800; CAS-57-43-2; component of Amo-Dextrosule (Salt/Mix); IDI1_000994; FT-0662116; C07536; D00555; 057A558; Q415850; 5-Ethyl-5-isopentyl-2,4,6(1H,3H,5H)-pyrimidinetrione #; Amylobarbitone|||Amytal|||5-Ethyl-5-isoamylbarbituric acid; Amobarbital solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; InChI=1/C11H18N2O3/c1-4-11(6-5-7(2)3)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16); AMAL
Amoxicillin [2S-[2alpha,5alpha,6beta(S*)]]-6-[[Amino(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Amopen; alpha-Amino-p-hydroxybenzylpenicillin
Amoxicillin trihydrate (2S,5R,6R)-6-[[(2R)-2-Amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid hydrate (1:3); Amoxicillin [USAN:USP:INN:BAN:JAN]; alpha-Amino-p-hydroxybenzylpenicillin trihydrate
Amphenicols Chloramphenicol; Florfenicol; Thiamphenicol
Amphotericin amphotericin b; 1397-89-3; Amphotericine B; Amfotericina B; Amphotericinum B; AMPH-B; Amphotericin; Fungizone; Liposomal Amphotericin B; Amphocin; Ambisome; Amphozone; Abelcet; Ampho-Moronal; Amphotericin-B; UNII-7XU7A7DROE; Amphotec; 7XU7A7DROE; MFCD00877763; NCGC00090808-01; Abelecet; Halizon; DSSTox_CID_2601; NSC 527017; DSSTox_RID_76653; DSSTox_GSID_22601; (1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36R,37S)-33-[(3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy]-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid; Amfotericina B [INN-Spanish]; Amphotericine B [INN-French]; Amphotericinum B [INN-Latin]; CCRIS 5963; HSDB 3008; Amphortericin B; Anfotericine B; EINECS 215-742-2; NS 718; BRN 0078342; AI3-26528; IAB; CHEBI:2682; Fungisome; Amphotericin B [USP:INN:JAN]; Fungizone (TN); Amphotec (TN); (1R-(1R*,3S*,5R*,6R*,9R*,11R*,15S*,16R*,17R*,18S*,19E,21E,23E,25E,27E,29E,31E,33R*,35S*,36R*,37S*))-33-((3-Amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy)-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo(33.3.1)nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid; (1S,3R,4E,6E,8E,10E,12E,14E,16E,18S,19R,20R,21S,25R,27R,30R,31R,33S,35R,37S,38R)-3-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyl-tetrahydropyran-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,12,14,16-heptaene-38-carboxylic acid; 14,39-Dioxabicyclo(33.3.1)nonatriaconta-19,21,23,25,2 7,29,31-heptaene-36-carboxylic acid, 33-((3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy)-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-(1R-(1R*,3S*,5R*,6R*,9R*,11R*,15S*,16R*,17R*,18S*,19E,21E,23E, 25E-27E,29E,31E,33R*,35S*,36R*,37S*))-; AmBisome (TN); Amp B; CAS-1397-89-3; Prestwick3_000410; Amphotericin B solubilized; SCHEMBL17973; BSPBio_000340; 5-18-10-00525 (Beilstein Handbook Reference); BIDD:GT0351; BPBio1_000374; NKTR-024; Amphotericin B and cinnamon oil; DTXSID9022601; APKFDSVGJQXUKY-INPOYWNPSA-N; HMS2096A22; HMS3713A22; Amphotericin B (JP17/USP/INN); HY-B0221; Tox21_111027; Tox21_202484; Amphotericin B from Streptomyces sp.; LMPK06000002; s1636; AKOS024464746; ZINC253387843; CCG-220410; CS-2169; DB00681; NCGC00260033-01; LS-187721; AB00513832; C06573; D00203; J10140; AB00513832_02; 397A893; Q412223; Amphotericin B from Streptomyces sp., ~80% (HPLC), powder; Amphotericin B, solubilized (45% Amphotericin B, 35% Sodium Deoxycholate); Amphotericin B from Streptomyces sp., BioReagent, suitable for cell culture, ~80% (HPLC); Amphotericin B solubilized, powder, gamma-irradiated, BioXtra, suitable for cell culture; (1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36R,37S)-33-[(3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy]-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-he; (1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36R,37S)-33-[(3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy]-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-hept; (1S,3R,4E,6E,8E,10E,12E,14E,16E,18S,19R,20R,21S,25R,27R,30R,31R,33S,35R,37S,38R)-3-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-; 23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,12,14,16-heptaene-38-carboxylic acid; Amphotericin B from Streptomyces sp., Vetec(TM) reagent grade, BioReagent, suitable for cell culture, ~80%; Amphotericin B solution, 250 mug/mL in deionized water, sterile-filtered, BioReagent, suitable for cell culture; amphotericin b; Fungizone; Fungilin; Ampho-Moronal; Amphotericin; Abelcet; Ambisome; Amphocin; Amphotec; Amphozone; C47H73NO17; Amfotericina B [INN-Spanish]; Amphotericine B [INN-French]; Amphotericinum B [INN-Latin]; CCRIS 5963; HSDB 3008; EINECS 215-742-2; NS 718; NSC 527017; 1397-89-3; BRN 0078342; AI3-26528; IAB; Fungisone; NSC527017; Amphotericin B, Streptomyces sp.; NSC-527017; Amphotericin B [USAN:INN:JAN]; Amphotericin B Colloidal Dispersion; (1R-(1R*,3S*,5R*,6R*,9R*,11R*,15S*,16R*,17R*,18S*,19E,21E,23E,25E,27E,29E,31E,33R*,35S*,36R*,37S*))-33-((3-Amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy)-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo(33.3.1)nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid; 14,39-Dioxabicyclo(33.3.1)nonatriaconta-19,21,23,25,2 7,29,31-heptaene-36-carboxylic acid, 33-((3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy)-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-(1R-(1R*,3S*,5R*,6R*,9R*,11R*,15S*,16R*,17R*,18S*,19E,21E,23E, 25E-27E,29E,31E,33R*,35S*,36R*,37S*))-; Prestwick_721; Amphotericin B Cholesterol Dispersion; Amphotericin .BETA.; amphotericin B liposomal; Amphotericin B (VAN8C; Prestwick2_000410; Amphotericin B, Lipid-based; CHEMBL364143; SCHEMBL8281075; HMS1569A22; LS-93; 14,21,23,25,27,29,31-heptaene-36-carboxylic acid, 33-[(3-amino-3,6-dideoxy-.beta.-D-mannopyranosyl)oxy]-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-,[1R-(1R*,3S*,5R*,6R*,9R*,11R*,15S*,16R*,17R*,18S*,19E,21E,23E,25E,27E,29E,31E,33R*,35S*,36R*,37S*)]-; WLN: T6-36- A AO RVO A&U C&U E&U G&U I&U K&U M&UTJ CVQ DQ FQ HQ JQ KQ NQ PQ T1 U1 VQ W1 O&O- BT6OTJ; Amphotericin; amphotericin b; CHEBI:2682; NSC-527017; Amphotericin B lipid complex; CHEMBL267345; Amphotericin b liposomal complex
Amphotericin B 5-18-10-00525 (Beilstein Handbook Reference)
Ampicillin (2S,5R,6R)-6-[[(2R)-2-Amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Ampicillin; P-50
Ampicillin sodium (2S,5R,6R)-6-[[(2R)-2-Amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, sodium salt (1:1); Ampicillin sodium [USAN:USP:JAN]; Alpen-N
Amsacrine N-[4-(9-Acridinylamino)-3-methoxyphenyl]methanesulfonamide; amsacrine; 51264-14-3; m-AMSA; Amsidine; Amsidyl; Acridinylanisidide; AmsacrimAMSA; Amsacrinum; Lamasine; Amekrin; Amsine; meta-Amsacrine; Acridinyl Anisidide; 4'-(9-Acridinylamino)-3'-methoxymethanesulfonanilide; 4'-(9-Acridinylamino)methanesulfon-m-anisidide; Amsacrinum [INN-Latin]; Amsacrina [INN-Spanish]; SN-11841; 4'-(9-Acridinylamino)methanesulphon-m-anisidide; N-[4-(acridin-9-ylamino)-3-methoxyphenyl]methanesulfonamide; CI-880; NSC249992; NSC 156303; NSC 249992; NSC-249992; C21H19N3O3S; 4'-(9-Acridinylamino)methanesulfon-meta-anisidide; SN 21429; UNII-00DPD30SOY; Methanesulfonamide, N-[4-(9-acridinylamino)-3-methoxyphenyl]-; NSC-156303; CCRIS 1027; HSDB 7087; CHEMBL43; N-[4-(9-Acridinylamino)-3-methoxyphenyl]methanesulfonamide; EINECS 257-094-3; CI 880; NSC-141549; BRN 0500176; 00DPD30SOY; CHEBI:2687; Methanesulfonanilide, 4'-(9-acridinylamino)-3'-methoxy-; N-(4-(9-Acridinylamino)-3-methoxyphenyl)methanesulfonamide; Methanesulfonamide, N-(4-(9-acridinylamino)-3-methoxyphenyl)-; XCPGHVQEEXUHNC-UHFFFAOYSA-N; Methanesulfon-m-anisidide, 4'-(9-acridinylamino)-; N-(4-(Acridin-9-ylamino)-3-methoxyphenyl)methanesulfonamide; N-[4-(acridin-9-ylamino)-3-(methyloxy)phenyl]methanesulfonamide; Cain's Acridine; meta-AMSA; Amecrin; MLS002153376; nAMSA; Amsacrine [USAN:BAN:INN]; Amsidyl (TN); Amsacrine (USAN/INN); SMR000875352; AMSA, M-; SN11841; Amsacrine [USAN:INN:BAN]; N-[4-(acridin-9-ylamino)-3-methoxyphenyl]methanesulfonamide; hydrochloride; Lopac-A-9809; NCIMech_000607; Neuro_000118; SCHEMBL4047; Lopac0_000154; 5-22-11-00030 (Beilstein Handbook Reference); MLS006010099; cid_148673; DTXSID4022604; BDBM87351; KS-00000TTN; HMS3748E05; N-[4-(9-Acridinylamino)-3-methoxy-phenyl]methanesulfonamide; N-[4-(acridin-9-ylamino)-3-methoxy-phenyl]methanesulfonamide; BCP08958; ZINC3812923; CCG-35555; AKOS015917522; API0001484; CS-1942; DB00276; LS-1319; NCI-249992; SDCCGSBI-0050142.P003; VA10050; NCGC00015113-01; NCGC00015113-02; NCGC00015113-03; NCGC00015113-04; NCGC00162077-01; AK547842; AS-11665; HY-13551; NCI60_001995; SMR000857391; SN-21429; WLN: T C666 BNJ IMR BO1 DMSW1; AB1004823; DB-082052; FT-0708980; C01553; D02321; 32319-EP2275420A1; 32319-EP2277865A1; 32319-EP2280012A2; 32319-EP2281815A1; 32319-EP2289892A1; 32319-EP2292615A1; 32319-EP2295055A2; 32319-EP2295416A2; 32319-EP2295426A1; 32319-EP2295427A1; 32319-EP2298748A2; 32319-EP2298764A1; 32319-EP2298765A1; 32319-EP2298768A1; 32319-EP2301928A1; 32319-EP2301933A1; 32319-EP2305640A2; 32319-EP2305642A2; 32319-EP2305671A1; 32319-EP2311453A1; 32319-EP2311808A1; 32319-EP2311827A1; 32319-EP2311829A1; 32319-EP2311840A1; 4'-(9-Acridinylamino)methanesulfonyl m-anisidide; 115830-EP2295416A2; 115830-EP2298748A2; 301A154; 4'-(9-Acridinylamino)-methylsulfonyl-m-anisidine; Q2784004; AMSA; m-AMSA; CI-880; SN-11841; acridinyl anisidide; N-[4-(9-acridinylamino)-3-methoxyphenyl]methanesulfonamide; hydrochloride; N-[4-(acridin-9-ylamino)-3-methoxy-phenyl]methanesulfonamide; hydrochloride; N-{4-[(ACRIDIN-9-YL)AMINO]-3-METHOXYPHENYL}METHANESULFONAMIDE; ASW; N-[4-(Acridin-9-ylamino)-3-(methyloxy)phenyl]methanesulfonamide; N-[4-(acridin-9-ylmethyl)-3-methoxyphenyl]methanesulfonamide; Amsacrine; 5-22-11-00030 (Beilstein Handbook Reference)
Amylamine 1-Pentanamine; Amylamine; Pentylamine; 1-Pentylamine; 110-58-7; 1-Aminopentane; pentan-1-amine; N-AMYLAMINE; 1-Pentanamine; Norleucamine; n-Pentylamine; Monoamylamine; amyl amine; UNII-E05QM3V8EF; CCRIS 6210; NSC 7906; EINECS 203-780-2; azahexane; BRN 0505953; E05QM3V8EF; n-C5H11NH2; AI3-15379; DPBLXKKOBLCELK-UHFFFAOYSA-N; n-Amylamine, 99%; monopentylamine; Azahexan; pentyl amine; n-pentyl amine; n--Amylamine; 3-ethyl-propylamine; Amylamine, 99%; n-AmNH2; ACMC-1BOY9; EC 203-780-2; Me(CH2)4NH2; Amylamine, >=99%, FG; 4-04-00-00674 (Beilstein Handbook Reference); KSC175Q1P; Amylamine, analytical standard; CH3(CH2)4NH2; DTXSID0021919; CHEBI:74848; CTK0H5817; KS-00000YUL; NSC7906; NSC-7906; STR07758; ZINC1586308; 7346AF; ANW-16169; BBL011398; LS-508; MFCD00008236; STL146502; AKOS000119067; DB02045; MCULE-6547961798; RTR-002170; TRA0086738; Amylamines, mixture of isomers, >=98%; SC-26821; TR-002170; A0445; FT-0622370; 11181-EP2316458A1; 11181-EP2316827A1; 12050-EP2289510A1; 12050-EP2316828A1; 14992-EP2287141A1; 14992-EP2289510A1; 14992-EP2316457A1; 10.14272/DPBLXKKOBLCELK-UHFFFAOYSA-N.1; 177854-EP2272830A1; 177854-EP2272831A1; 178577-EP2272830A1; Q766883; doi:10.14272/DPBLXKKOBLCELK-UHFFFAOYSA-N.1; J-002450; J-519589; F2190-0404; InChI=1/C5H13N/c1-2-3-4-5-6/h2-6H2,1H; n-Amylamine; 4-04-00-00674 (Beilstein Handbook Reference)
Andrographolide (3E,4S)-3-[2-[(1R,4aS,5R,6R,8aS)-Decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethylidene]dihydro-4-hydroxy-2(3H)-furanone; Andropanolide; 869807-57-8; 5508-58-7; CHEMBL466345; SCHEMBL15263160; HY-N1912; 9092AF; ZINC34169003; AKOS024458261; CS-0017906; (3E,4S)-3-[2-[(1R,4aS,5R,6R,8aS)-Decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethylidene]dihydro-4-hydroxy-2(3H)-furanone; Andrographolide; Andrographis
Androstanolone (5alpha,17beta)-17-Hydroxyandrostan-3-one; dihydrotestosterone; STANOLONE; Androstanolone; 521-18-6; Andractim; Androlone; Anaboleen; Anabolex; ProteiStanaprol; Neodrol; ProtoCristerona MB; 4-Dihydrotestosterone; 5alpha-Dihydrotestosterone; 17beta-Hydroxy-5alpha-androstan-3-one; DHT; AndrostanoloAndrostanolonum; 5alpha-Androstan-17beta-ol-3-one; 5-alpha-Dihydrotestosterone; Testosterone, dihydro-; 4,5alpha-Dihydrotestosterone; Stanolon; Stanorone; Dihydrotestosteron; 17beta-Hydroxyandrostan-3-one; 5alpha-DHT; LG 152; 17beta-Hydroxy-3-androstanone; 5alpha-Dihydroxytestosterone; Androstan-17beta-ol-3-one; NSC 10972; 5alpha,17beta-Hydroxyandrostan-3-one; Androstanolonum [INN-Latin]; Androstanolona [INN-Spanish]; 4,5-alpha-Dihydrotestosterone; UNII-08J2K08A3Y; CHEBI:16330; 17-beta-Hydroxy-5-alpha-androstan-3-one; 5alpha-dihydrotesosterone; 5alpha dihydrotestosterone; EINECS 208-307-3; 5alpha,17eta-Hydroxyandrostan-3-one; 5-alpha-Androstan-17-beta-ol-3-one; 5.alpha.-Dihydrotestosterone; CHEMBL27769; (5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one; 4,5.alpha.-Dihydrotestosterone; (5alpha,17beta)-17-hydroxyandrostan-3-one; 17beta-Hydroxy-androstan-3-one; 5-alpha-Androstan-3-one, 17-beta-hydroxy-; Androstan-3-one, 17-hydroxy-, (5a,17b)-; 17.beta.-Hydroxy-3-androstanone; (5-alpha,17-beta)-17-Hydroxyandrostan-3-one; NVKAWKQGWWIWPM-ABEVXSGRSA-N; 08J2K08A3Y; Androstan-3-one, 17-hydroxy-, (5alpha,17beta)-; NSC-10972; Androstanolone (INN); Androstanolone [INN]; 17beta-Hydroxy-5alpha-androstane-3-one; 5.alpha.-Androstan-17.beta.-ol-3-one; NCGC00091013-01; 5alpha-Androstan-3-one, 17beta-hydroxy-; 5.alpha.,17.beta.-Hydroxyandrostan-3-one; DSSTox_CID_2364; DSSTox_RID_76558; DSSTox_GSID_22364; [3H]DHT; Stanolone [BAN]; CAS-521-18-6; 5-.alpha.-Androstanolone; 5.alpha.-Androstan-3-one, 17.beta.-hydroxy-; 17-Hydroxyandrostan-3-one; [3H]dihydrotestosterone; [3H]-dihydrotestosterone; Androstan-17.beta.-ol-3-one; Andrin; (+)-Androstan-17.beta.-ol-3-one; 1kdk; 2ama; Andractim (TN); (5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-10,13-dimethyltetradecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one; 5-a-Androstanolone; 5alpha-Androstanolone; 5a-Dihydrotestosterone; 17-.beta.-Hydroxy-5-.alpha.-androstan-3-one; 5-alpha-Androstanolone; 1d2s; 1t5z; 1t7r; dihydrotestosterone (dht); (5.alpha.,17.beta.)-17-Hydroxy-androstan-3-one; 4,5a-Dihydrotestosterone; Androstan-17b-ol-3-one; Epitope ID:135868; 17-Hydroxyandrostan-3-one, (5.alpha.,17.beta.)- #; EC 208-307-3; 17b-Hydroxy-3-androstanone; BIDD:PXR0075; SCHEMBL15163; 17-Hydroxy-androstan-3-one; MLS001304063; 5a-Androstan-17b-ol-3-one; BIDD:ER0136; 5.alpha.-Dihydroxytestosterone; 5A-Androstan-3-on-17B-ol; 5B-Androstan-3-on-17B-ol; GTPL2856; GTPL3455; 17-beta-hydroxyandrostan-3-one; DTXSID9022364; BDBM18161; 1t63; (+)-Androstan-17beta-ol-3-one; HMS2272H05; HY-A0120; NSC10972; ZINC3814360; Tox21_111056; Tox21_200987; Tox21_303655; BDBM50366473; LMST02020042; s4757; AKOS015894892; API0004234; CS-5096; DB02901; EBD2157869; GS-6587; MCULE-5987413622; NCGC00091013-02; NCGC00091013-03; NCGC00257456-01; NCGC00258540-01; 17beta-hydroxy-3-oxo-5alpha-androstanone; AC-16144; AK173346; CC-34536; LS-19384; SC-16121; SMR000058342; AB0108935; 5alpha-Androstan-17beta-ol-3-one, >=97.5%; C03917; D07456; Z-2983; 521S186; 5alpha-Androstan-3-one, 17beta-hydroxy- (8CI); C-18235; Q411054; Androstanolone (5alpha-Dihydrotestosterone; Stanolone); Androstan-3-one, 17-hydroxy-, (5alpha,17beta)- (9CI); 5alpha-Androstan-17beta-ol-3-one, purum, >=99.0% (TLC); 5alpha-Androstan-17beta-ol-3-one, VETRANAL(TM), analytical standard; Androstanolone (5alpha-Dihydrotestosterone; Stanolone) 1.0 mg/ml in Acetonitrile; (1S,2S,7S,10R,11S,14S,15S)-14-hydroxy-2,15-dimethyltetracyclo[8.7.0.0; {2,7}.0; {11,15}]heptadecan-5-one; (1S,2S,7S,10R,11S,14S,15S)-14-hydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-5-one; (5S,8R,10S,13S,17S)-17-Hydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-3-one; 17-hydroxy-10,13-dimethyl-1,2,4,5,6,7,8,9,10,11,12,13,14,15,16, 17-hexadecahydrocyclopenta[a]phenanthren-3-one; 5alpha-Dihydrotestosterone (DHT) solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; Dihydrotestosterone; Anaboleen
Androstenediol (3beta,17beta)-Androst-5-ene-3,17-diol; Androstenediol; Hermaphrodiol; 5-Androstenediol; Androst-5-enediol; 521-17-5; Androst-5-ene-3beta,17beta-diol; Neumune; 3beta,17beta-Dihydroxyandrost-5-ene; delta(sup 5)-Androstenediol; Androstenediol [JAN]; UNII-95PS51EMXY; Androst-5-enediol (VAN); (3beta,17beta)-androst-5-ene-3,17-diol; 5-AED; 3beta,17beta-Dihydroxy-5-androstene; HE2100; androst-5-en-3beta,17beta-diol; EINECS 208-306-8; NSC 12163; 95PS51EMXY; ANDROST-5-ENE-3-beta,17-beta-DIOL; Androst-5-ene-3,17-diol, (3b,17b)-; CHEBI:2710; CHEMBL440283; (3-beta,17-beta)-Androst-5-ene-3,17-diol; delta(sup 5)-Androstene-3-beta,17-beta-diol; QADHLRWLCPCEKT-LOVVWNRFSA-N; Androst-5-ene-3,17-diol; Androstenediol (JAN); NCGC00167494-01; DSSTox_CID_2609; DSSTox_RID_76657; DSSTox_GSID_22609; CAS-521-17-5; Delta 5-Androstenediol; 5-Androstene-3,17-diol; Tetrabol; NSC-12163; 5-andendiol; 5-Androstene-3beta-17beta-Diol; beta-AED; Tetrabol (TN); Androst-5-ene-3 beta,17 beta-diol; b,17b-diol; delta5-Androstenediol; delta-5-Androstenediol; delta 5-Androstene-3 beta,17 beta-diol; Androst-5-ene-3,17-diol, (3beta,17beta)-; BIDD:PXR0074; SCHEMBL27485; Androst-5-ene-3b,17b-diol; Androst-5-ene-3,17-diol #; DTXSID9022609; 5-Androstene-3beta,17beta-diol; Androst-5-ene-3-ss,17-ss-diol; (3S,8R,9S,10R,13S,14S,17S)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,17-diol; ZINC3814414; Tox21_112495; BDBM50223237; LMST02020005; 3beta,17beta-dihydroxy-androst-5-en; AKOS015955537; Tox21_112495_1; API0001495; DB01524; HE-2100; NCGC00263558-01; AC-12166; Androst-5-ene, 3beta,17beta-dihydroxy-; LS-19427; 13-Iso-androst-5-en-3.beta.,17.beta.-diol; C04295; D00179; 521A175; Androst-5-ene-3,17-diol, (3-beta,17-beta)-; (3alpha,8alpha,17beta)-androst-5-ene-3,17-diol; Q2817108; W-105849; Androst-5-ene-3,17-diol, (3beta,17beta)- (9CI); 017E86D6-684F-4DB1-90E0-55C1467FF85B; (3S,8R,10R,13S,17S)-10,13-Dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,17-diol; B81; Androstenediol; Androstenediol
Androstenedione Androst-4-ene-3,17-dione; androstenedione; 4-Androstene-3,17-dione; Androst-4-ene-3,17-dione; 63-05-8; 4-Androstenedione; Androtex; 3,17-Dioxoandrost-4-ene; delta-4-Androstenedione; SKF 2170; Fecundin; delta-4-Androstene-3,17-dione; 4-ANDROSTENE-3-17-DIONE; delta-4-Androsten-3,17-dione; Androstendione; 4-Androsten-3,17-dione; NSC 9563; delta-(sup4)-Androsten-3,17-dione; delta(sup 4)-Androstene-3,17-dione; 17-Ketotestosterone; UNII-409J2J96VR; CHEBI:16422; Androstenedione [JAN]; HSDB 7335; EINECS 200-554-5; MLS000028510; (8R,9S,10R,13S,14S)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-3,17-dione; Delta(4)-androsten-3,17-dione; NSC9563; AEMFNILZOJDQLW-QAGGRKNESA-N; 409J2J96VR; Delta(4)-androstene-3,17-dione; .DELTA.4-Androstene-3,17-dione; Androstenedione (JAN); NCGC00023902-06; SMR000058281; DSSTox_CID_4523; DSSTox_RID_77443; DSSTox_GSID_24523; CAS-63-05-8; (8R,9S,10R,13S,14S)-10,13-dimethyl-7,8,9,10,11,12,13,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-3,17(2H,6H)-dione; CHEMBL274826; adione; DELTA4-Androstene-3,17-dione; delta4-androstenedione; Androsten-3,17-dione; Opera_ID_1694; Spectrum5_002059; [4-14C]-androstenedione; Epitope ID:135869; EC 200-554-5; Testosterone EP Impurity A; androst-4-en-3,17-dione; BIDD:PXR0101; D4-Androstene-3,17-dione; Lopac0_000114; SCHEMBL23272; KSC353K6T; MLS000563086; MLS002152886; (4)-Androsten-3,17-dione; GTPL2860; DTXSID8024523; BDBM91713; CTK2F3569; .delta.4-Androsten-3,17-dione; Androst-4-en-3,17-dione, 2; HMS2231F18; NSC-9563; ZINC4428526; Tox21_110893; Tox21_202269; Tox21_300579; BBL033517; c1015; LMST02020007; MFCD00003615; STK801871; AKOS005622710; Tox21_110893_1; [4-14C]androst-4-ene-3,17-dione; CCG-204209; DB01536; LS-2167; MCULE-8902385122; RTR-021722; SHG0000068; .delta.-(sup4)-Androsten-3,17-dione; Estr-5-ene-3,17-diol,(3b,17b)-; NCGC00023902-03; NCGC00023902-04; NCGC00023902-05; NCGC00023902-07; NCGC00023902-08; NCGC00023902-09; NCGC00254238-01; NCGC00259818-01; AC-11042; Androstenedione; 3,17-Dioxo-4-andostene; SC-46873; VS-12118; AB0090630; A0845; androst-4-ene-3,17-dione (androstenedione); EU-0100114; FT-0082072; FT-0657562; Androstenedione (Androst-4-ene-3,17-dione); WLN: L E5 B666 FV OV MUTJ A1 E1; A 9630; C00280; D00051; Q411064; SR-01000003096; SR-01000075697; SR-01000003096-4; SR-01000075697-1; W-104936; 4-Androstene-3,17-dione 100 microg/mL in Methanol/Water; 8F5F4DCB-1164-4F2C-B4E3-3B74F684B189; 4-Androstene-3,17-dione, VETRANAL(TM), analytical standard; Androstenedione (Androst-4-ene-3,17-dione) 1.0 mg/ml in Acetonitrile; (3aS,3bR,9aR,9bS,11aS)-9a,11a-dimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthrene-1,7-dione; (8R,10R,13S)-10,13-Dimethyl-1,6,7,8,9,10,11,12,13,14,15,16-dodecahydro-2H-cyclopenta[a]phenanthrene-3,17-dione; 117598-81-9; Androst-4-ene-3,17-dione; 17-Ketotestosterone; Androstenedione; 4-Androstene-3,17-dione; 4-Androstenedione; Androstenedione; delta-4-Androsten-3,17-dione
Angiotensina II Angiotensin II
Anisomycin 2-[(4-Methoxyphenyl)methyl]-3,4-pyrrolidinediol (2R,3S,4S)-3-acetate; Anisomycin; 5-21-05-00523 (Beilstein Handbook Reference)
Ansamycins Rifabutin; Rifampicin; Rifamycin; Rifapentine; Rifamixin
Anthranilic acid 2-Aminobenzoic acid; o-Aminobenzoic acid; 4-27-00-07875 (Beilstein Handbook Reference)
Anti-inflammatory unspecified (AI) Anti-inflammatory unknown; Anti-inflammatory unspecified; Anti-inflammatory generic; Anti-inflammatories unknown; Anti-inflammatories unspecified; Anti-inflammatories generic; Anti-inflammatories; Antiinflammatory; Antiinflammatories
Antibiotic unspecified (AI) Antibiotic unknown; Antibiotic unspecified; Antibiotic generic; Antibiotics unknown; Antibiotics unspecified; Antibiotics generic; Antibiotics
Antimycin A1 2(or 3)-Methylbutanoic acid, (2R,3S,6S,7R,8R)-3-[[3-(formylamino)-2-hydroxybenzoyl]amino]-8-hexyl-2,6-dimethyl-4,9-dioxo-1,5-dioxonan-7-yl ester; Antimycin A1; Antimycin A1
Antiparasitics unspecified (AI) Antiparasitic unknown; Antiparasitic unspecified; Antiparasitic generic; Antiparasitics unknown; Antiparasitics unspecified; Antiparasitics generic; Antiparasitics
Antipyrine 1,2-Dihydro-1,5-dimethyl-2-phenyl-3H-pyrazol-3-one; antipyrine; Phenazone; 60-80-0; Antipyrin; Phenazon; Analgesine; Anodynine; Anodynin; Azophen; Fenazone; 2,3-Dimethyl-1-phenyl-5-pyrazolone; Antipirin; Phenozone; Apirelina; Azophene; Methozin; Phenylone; Pyrazophyl; Sedatine; Sedatin; Dimethyloxychinizin; Antipyrinum; Dimethyloxyquinazine; Oxydimethylquinazine; Phenazonum; Azophenum; Parodyne; Phenylon; 3-Antipyrine; Fenazon [Czech]; Fenazona; 3H-Pyrazol-3-one, 1,2-dihydro-1,5-dimethyl-2-phenyl-; Fenazona [INN-Spanish]; Phenazone (pharmaceutical); Fenazon; Oxydimethylquinizine; 2,3-Dimethyl-1-phenyl-3-pyrazolin-5-one; 1-Phenyl-2,3-dimethyl-5-pyrazolone; 1-Phenyl-2,3-dimethylpyrazole-5-one; 1,2-Dihydro-1,5-dimethyl-2-phenyl-3H-pyrazol-3-one; CHEBI:31225; Phenazonum [INN-Latin]; UNII-T3CHA1B51H; NSC 7945; 1,5-Dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one; 1,5-dimethyl-2-phenylpyrazol-3-one; CCRIS 1369; EINECS 200-486-6; T3CHA1B51H; 1,5-dimethyl-2-phenyl-2,3-dihydro-1H-pyrazol-3-one; AI3-15293; VEQOALNAAJBPNY-UHFFFAOYSA-N; Phenazone (INN); Phenazone [INN]; NSC-7945; Antipyrine, 99%; CAS-60-80-0; NCGC00016274-04; DSSTox_CID_1117; DSSTox_RID_75949; DSSTox_GSID_21117; Antipyrine [JAN]; SMR000238140; Antipyrine [USP:JAN]; SR-05000001566; .beta.-Antipyrine; Prestwick_26; Antipyrine Crystals; MFCD00003146; component of Auralgan; 1,5-dimethyl-2-phenyl-pyrazol-3-one; Spectrum_000058; Prestwick0_000029; Prestwick1_000029; Prestwick2_000029; Prestwick3_000029; Spectrum2_000088; Spectrum3_000305; Spectrum4_000152; Spectrum5_000842; ACMC-209mm6; Antipyrine (JP17/USP); Epitope ID:124927; EC 200-486-6; 1,5-dimethyl-2-phenyl-1H-pyrazol-3(2H)-one; ANTIPYRINE CRYSTALLINE; SCHEMBL20452; BSPBio_000097; BSPBio_001870; KBioGR_000624; KBioSS_000438; KSC912A0P; MLS001331753; MLS001332401; MLS001332402; MLS002154179; DivK1c_000484; SPECTRUM1500128; SPBio_000016; SPBio_002018; Antipyrine, analytical standard; BPBio1_000107; CHEMBL277474; DTXSID6021117; CTK8B2007; HMS501I06; KBio1_000484; KBio2_000438; KBio2_003006; KBio2_005574; KBio3_001370; ZINC61044; NSC7945; Antipyrine, >=99.0% (RT); NINDS_000484; HMS1568E19; HMS1920E09; HMS2091K09; HMS2095E19; HMS2272G04; HMS3652C09; HMS3712E19; Pharmakon1600-01500128; WLN: T5NNVJ A1 BR& E1; HY-B0171; KS-000010VJ; Tox21_110342; Tox21_201600; Tox21_303026; Antipyrine, Sigma Reference Standard; ANW-33580; BBL001832; BDBM50103600; CCG-38904; NSC755874; s3173; SBB017226; STK328171; 1,5-Dimethyl-2-phenyl-3-pyrazolone; AKOS000588788; Tox21_110342_1; CS-2044; DB01435; LS-7645; MCULE-9945022433; NSC-755874; RTR-020954; IDI1_000484; Antipyrine, analytical reference material; Antipyrine, tested according to Ph.Eur.; NCGC00016274-01; NCGC00016274-02; NCGC00016274-03; NCGC00016274-05; NCGC00016274-06; NCGC00016274-07; NCGC00016274-10; NCGC00094591-01; NCGC00094591-02; NCGC00094591-03; NCGC00178937-01; NCGC00178937-02; NCGC00256527-01; NCGC00259149-01; AS-13248; H725; SC-25842; ST009485; SBI-0051287.P003; AB1009247; Antipyrine, Vetec(TM) reagent grade, 98%; TR-020954; D1876; FT-0609690; SW196343-3; A19580; BIM-0051287.0001; C13244; D01776; AF-960/00437050; Q415578; Q-201552; SR-05000001566-1; SR-05000001566-3; 2,3-Dimethyl-1-phenyl-3-pyrazolin-5-one; Phenazone; BRD-K46937689-001-05-1; BRD-K46937689-001-08-5; Z56869297; F2173-0728; 1,5-Dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one #; Phenazone, European Pharmacopoeia (EP) Reference Standard; Antipyrine, United States Pharmacopeia (USP) Reference Standard; 1,2-Dihydro-1,5-dimethyl-2-phenyl-3H-pyrazol-3-one; Phenazone; Antipyrine; AI3-15293
Antiviral unspecified (AI) Antiviral unknown; Antiviral unspecified; Antiviral generic; Antivirals unknown; Antivirals unspecified; Antivirals generic; Antivirals
Apigenin 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; apigenin; 520-36-5; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; Chamomile; Versulin; Spigenin; Apigenol; 4',5,7-Trihydroxyflavone; Apigenine; C.I. Natural Yellow 1; Pelargidenon 1449; 5,7,4'-Trihydroxyflavone; NSC 83244; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4-benzopyrone; 5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one; 2-(p-Hydroxyphenyl)-5,7-dihydroxychromone; UCCF 031; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-(4-hydroxyphenyl)-; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; UNII-7V515PI7F6; CCRIS 3789; CHEBI:18388; 4′ ,5,7-Trihydroxyflavone; CHEMBL28; EINECS 208-292-3; MFCD00006831; BRN 0262620; FLAVONE, 4',5,7-TRIHYDROXY-; KZNIFHPLKGYRTM-UHFFFAOYSA-N; 7V515PI7F6; NSC83244; NSC-83244; AK-88794; CAS-520-36-5; ST056301; DSSTox_CID_2391; DSSTox_RID_76568; DSSTox_GSID_22391; 8002-66-2; Q-100586; Q-200822; SMR000326850; SR-01000075663; Chamomile Powder; HSDB 7573; 4der; 4dgm; 4hkk; Naringenin, 18; Prestwick_719; Apigenin, 13; PubChem9831; Tocris-1227; 3cf9; 4',7-Trihydroxyflavone; BiomolKI_000078; Prestwick0_000414; Prestwick1_000414; Prestwick2_000414; Prestwick3_000414; Spectrum2_000428; Spectrum3_001882; Spectrum4_001999; Lopac-A-3145; BiomolKI2_000082; 4,5, 7-Trihydroxyflavone; Lopac0_000065; Oprea1_622293; SCHEMBL19428; 4',5,7-trihydroxy-Flavone; Apigenin, analytical standard; BSPBio_000368; BSPBio_003384; KBioGR_002565; SPECTRUM200846; 5-18-04-00574 (Beilstein Handbook Reference); MLS000697626; MLS000859991; MLS001074874; MLS006011839; BIDD:ER0135; DivK1c_000798; SCHEMBL222227; SPBio_000416; SPBio_002307; ghl.PD_Mitscher_leg0.1194; BDBM7458; BPBio1_000406; GTPL4136; MEGxp0_000176; DTXSID6022391; ACon1_002450; cid_5280443; HMS502H20; KBio1_000798; KBio3_002887; BIK9018; OR7265T; NINDS_000798; ZX-AFC000435; Bio1_000376; Bio1_000865; Bio1_001354; HMS1569C10; HMS1922P22; HMS2096C10; HMS2230D17; HMS3260M11; HMS3267D21; HMS3373B18; HMS3412A08; HMS3561P09; HMS3655D18; HMS3676A08; Apigenin, >=95.0% (HPLC); 4',5,7-Trihydroxyflavone, 97%; ACN-S003241; BCP28288; HY-N1201; ZINC3871576; ZX-AT019281; Tox21_201542; Tox21_302884; Tox21_500065; Apigenin; 4',5,7-Trihydroxyflavone; BBL010499; BS0030; CCG-40061; GP1532; HSCI1_000221; LMPK12110005; s2262; SBB066087; STK801630; AKOS002140699; AC-8011; ACN-034762; CS-5432; DB07352; EBD2138579; LP00065; LS-2209; MCULE-6141069907; ND-9076; SDCCGMLS-0066379.P001; SDCCGSBI-0050053.P003; TRA0067512; IDI1_000798; SMP2_000338; Apigenin, >=97% (TLC), from citrus; NCGC00015049-01; NCGC00015049-02; NCGC00015049-03; NCGC00015049-04; NCGC00015049-05; NCGC00015049-06; NCGC00015049-07; NCGC00015049-08; NCGC00015049-09; NCGC00015049-10; NCGC00015049-11; NCGC00015049-12; NCGC00015049-13; NCGC00015049-14; NCGC00015049-15; NCGC00015049-16; NCGC00015049-18; NCGC00025057-01; NCGC00025057-02; NCGC00025057-03; NCGC00025057-04; NCGC00025057-05; NCGC00025057-06; NCGC00025057-07; NCGC00025057-08; NCGC00025057-09; NCGC00169835-01; NCGC00169835-02; NCGC00169835-03; NCGC00256419-01; NCGC00259092-01; NCGC00260750-01; 4CN-0925; CC-24158; NCI60_041830; SC-05011; SY005957; TS-00897; AB0010536; AB1011450; AX8015784; ST2411642; TC-307820; TR-018510; EU-0100065; FT-0622445; FT-0623582; N1828; SW196866-2; 20A365; A 3145; C01477; J10341; K00045; M-6923; Apigenin, >=97% (TLC), from parsley, powder; Biochem Biophys Res Comm 212: 767 (1997); 4 inverted exclamation marka,5,7-Trihydroxyflavone; 5,7-dihydroxy-2-(4-hydroxyphenyl)-chromen-4-one; Apigenin, primary pharmaceutical reference standard; C-16977; Q424567; 4 inverted exclamation mark ,5,7-trihydroxyflavone; SR-01000075663-1; SR-01000075663-3; SR-01000075663-7; SR-01000075663-8; BRD-K01493881-001-10-4; BRD-K01493881-001-17-9; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one #; 4H-1-Benzopyran-4-one,7-dihydroxy-2-(4-hydroxyphenyl)-; D50A2D8A-6D8B-4708-B21E-2DE9580D033F; Apigenin, United States Pharmacopeia (USP) Reference Standard; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-(4-hydroxyphenyl)- (9CI); Apigenin; 5-18-04-00574 (Beilstein Handbook Reference)
Apomorphine (6aR)-5,6,6a,7-Tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diol; Apomorphine; Apomorfin
Apramycin sulphate Apramycin sulfate; Apramycin (sulphate); Apramycin (sulfate); (2R,3R,4S,5S,6S)-2-[[(2R,3S,4R,4aR,6S,7R,8aS)-7-amino-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2,3-dihydroxycyclohexyl]oxy-4-hydroxy-3-(methylamino)-2,3,4,4a,6,7,8,8a-octahydropyrano[3,2-b]pyran-2-yl]oxy]-5-amino-6-(hydroxymethyl)oxane-3,4-diol sulfuric acid; (2R,3R,4S,5S,6S)-2-[[(2R,3S,4R,4aR,6S,7R,8aS)-7-amino-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2,3-dihydroxycyclohexyl]oxy-4-hydroxy-3-(methylamino)-2,3,4,4a,6,7,8,8a-octahydropyrano[3,2-b]pyran-2-yl]oxy]-5-amino-6-(hydroxymethyl)oxane-3,4-diol; sulfuric acid; (2R,3R,4S,5S,6S)-5-amino-2-(((2R,3S,4R,4aR,6S,7R,8aS)-7-amino-6-(((1R,2R,3S,4R,6S)-4,6-diamino-2,3-dihydroxycyclohexyl)oxy)-4-hydroxy-3-(methylamino)octahydropyrano[3,2-b]pyran-2-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4-diol sulfate; UNII-8UYL6NAZ3Q; EINECS 265-890-7; Apramycin sulfate salt; Apramycin sulphate salt; 410097-64-2; AI3-29795; 8UYL6NAZ3Q; 65710-07-8; C21H43N5O15S
Arachidonic acid (5Z,8Z,11Z,14Z)-5,8,11,14-Eicosatetraenoic acid; Arachidonic acid; AI3-09613
Arsenical antibiotics Roxarsone; Nitarsone; Arsanilic Acid; Carbarsone
Arsorite Arsenite (AsO3); Arsenite; Arsenite
Asparagine L-Asparagine; L-asparagine; asparagine; 70-47-3; (S)-asparagine; Aspartamic acid; agedoite; altheine; H-Asn-OH; Crystal VI; Asparamide; asparagine acid; (S)-2,4-diamino-4-oxobutanoic acid; (-)-asparagine; L-Aspartamine; alpha-aminosuccinamic acid; Asparagine, L-; L-2,4-diamino-4-oxobutanoic acid; (2S)-2-amino-3-carbamoylpropanoic acid; L-b-Asparagine; aspartic acid beta-amide; Asparagine (VAN); 2-Aminosuccinamic acid; ASN; L-beta-Asparagine (VAN); 2-aminosuccinamic acid, L-; butanoic acid, 2,4-diamino-4-oxo-, (S)-; L-asparatamine; L-Asparagine anhydrous; L-2-aminosuccinamic acid; NSC 82391; L-aspartic acid beta-amide; (2S)-2,4-diamino-4-oxobutanoic acid; 2,4-diamino-4-oxobutanoic acid, (S)-; CHEBI:17196; DCXYFEDJOCDNAF-REOHCLBHSA-N; MFCD00064401; (S)-2-amino-3-carbamoylpropanoic acid; L-Asparagine, 99%; L-beta-asparagine; (S)-2-Aminosuccinic acid 4-amide; L-Asn; L-.beta.-Asparagine; Aspartic acid b-amide; a-Aminosuccinamic acid; UNII-7NG0A2TUHQ; aspargine; Aspartamate; L-Asparagin; HSDB 7425; a-Aminosuccinamate; 2-Aminosuccinamate; EINECS 200-735-9; Asn-OH; alpha-Aminosuccinamate; 4-imino-L-homoserine; alpha Amminosuccinamate; L-Asparagine (9CI); PubChem15166; H-Asn-OH H; Aspartic acid beta amide; N-Lauryl-N-methyltaurine; 7NG0A2TUHQ; ASN NH3+ COOH; alpha Amminosuccinamic acid; Asparagine, L- (8CI); bmse000030; bmse000912; Aspartic acid .beta. amide; L-alpha-Aminosuccinamic Acid; UNII-5Z33R5TKO7; .alpha.-Aminosuccinamic acid; L-(+)-Asparagine anhydrous; KSC222G3N; CHEMBL58832; ASPARAGINE (L) HYDRATE; 5Z33R5TKO7; GTPL4533; SCHEMBL3126352; L-2,4-Diamino-4-oxobutanoate; US9138393, L-Asparigine; US9144538, L-Asparigine; CTK1C2336; KS-00000KPN; DTXSID10883220; BDBM181137; Pharmakon1600-01301002; (S)-2,4-Diamino-4-oxobutanoate; L-Asparagine, >=98% (HPLC); HY-N0667; STR07164; ZINC1532556; B2,4-(S)-diamino-4-oxo-utanoate; NSC760099; s5571; AKOS006239067; AC-4657; AM81554; DB00174; MCULE-1868046141; NSC-760099; RTR-037552; B2,4-(S)-diamino-4-oxo-utanoic acid; NCGC00344576-01; BP-23453; K189; SC-09349; AB0014082; AB1002642; TR-037552; A0542; CS-0009702; FT-0627706; ST24035780; L-Asparagine, Vetec(TM) reagent grade, 98%; C-4711; C00152; 47600-EP2270018A1; 47600-EP2298780A1; 47600-EP2305689A1; 47600-EP2311811A1; 47600-EP2374788A1; 064A401; Q29519883; F1905-7151; Z1270387291; (S)-2-Aminosuccinic acid 4-amide; L-Aspartic acid 4-amide; 3C28F6A9-E581-4255-ACCF-F75597AB288F; L-Asparagine, certified reference material, TraceCERT(R); UNII-0O72R8RF8A component DCXYFEDJOCDNAF-REOHCLBHSA-N; UNII-832C8OV84S component DCXYFEDJOCDNAF-REOHCLBHSA-N; Asparagine anhydrous, United States Pharmacopeia (USP) Reference Standard; L-Asparagine, BioReagent, suitable for cell culture, suitable for insect cell culture; Asparagine; Agedoite
Aspartame L-alpha-Aspartyl-2-methyl ester L-phenylalanine; Aspartame; 3-Amino-N-(alpha-carboxyphenethyl)succinamic acid N-methyl ester
Aspergillic acid BRN 0882390
Astemizole astemizole; 68844-77-9; Hismanal; Histaminos; Paralergin; Laridal; Retolen; Alermizol; Astemison; Histamen; Kelp; Astemizol; Astemizolum; Hestazol; Wareezol; Metodih; Novo-mastizol A; Astemizol [German]; Astemizol [INN-Spanish]; Astemizolum [INN-Latin]; C28H31FN4O; CCRIS 7595; R 42512; GNF-PF-2461; HSDB 6799; UNII-7HU6337315; 1-(p-Fluorobenzyl)-2-((1-(2-(p-methoxyphenyl)ethyl)piperid-4-yl)amino)benzimidazole; 1-(p-Fluorobenzyl)-2-((1-(p-methoxyphenethyl)-4-piperidyl)amino)benzimidazole; 1-[(4-Fluorophenyl)methyl]-N-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]-1H-benzimidazol-2-amine; Astemisan; EINECS 272-441-9; R-43512; BRN 4830190; MLS000028667; CHEBI:2896; CHEMBL296419; Histazol; GXDALQBWZGODGZ-UHFFFAOYSA-N; NCGC00016913-08; Metodik; SMR000058911; Waruzol; CAS-68844-77-9; DSSTox_CID_110; 7HU6337315; 1-(4-Fluorobenzyl)-2-(1-[4-methoxyphenethyl]piperidin-4-yl)aminobenzimidazole; Benzimidazole, 1-(p-fluorobenzyl)-2-((1-(2-(p-methoxyphenyl)ethyl)piperid-4-yl)amino)-; DSSTox_RID_75373; DSSTox_GSID_20110; 1-((4-Fluorophenyl)methyl)-N-(1-(2-(4-methoxyphenyl)ethyl)-4-piperidinyl)- 1H-benzimidazol-2-amine; 1H-Benzimidazol-2-amine, 1-((4-fluorophenyl)methyl)-N-(1-(2-(4-methoxyphenyl)eth l)-4-piperidinyl)-; 1H-Benzimidazol-2-amine, 1-((4-fluorophenyl)methyl)-N-(1-(2-(4-methoxyphenyl)ethyl)-4-piperidinyl)-; 1H-Benzimidazol-2-amine, 1-[(4-fluorophenyl)methyl]-N-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]-; W-104654; Novo-nastizol a; [3H]Astemizole; 1-(4-fluorobenzyl)-2-(1-(4-methoxyphenethyl)piperidin-4-yl)aminobenzimidazole; 1-(4-fluorobenzyl)-N-{1-[2-(4-methoxyphenyl)ethyl]piperidin-4-yl}-1H-benzimidazol-2-amine; 1-(p-Fluorobenzyl)-2-[[1-(p-methoxyphenethyl)-4-piperidyl]amino]benzimidazole; 1-[(4-fluorophenyl)methyl]-N-(1-{2-[4-(methyloxy)phenyl]ethyl}piperidin-4-yl)-1H-benzimidazol-2-amine; 1-[(4-fluorophenyl)methyl]-N-{1-[2-(4-methoxyphenyl)ethyl]piperidin-4-yl}-1H-1,3-benzodiazol-2-amine; Astemizole [USAN:BAN:INN]; SR-01000003168; HISMANAL (TN); Astemizole (JAN/USP/INN); MJD-30; Astemizole,(S); Prestwick_35; R-43-512; Astemizole [USAN:USP:INN:BAN:JAN]; Opera_ID_62; Spectrum_000448; Prestwick0_000136; Prestwick1_000136; Prestwick2_000136; Prestwick3_000136; Spectrum2_001732; Spectrum3_001072; Spectrum4_001223; Spectrum5_001239; UPCMLD-DP024; cid_2247; SCHEMBL4385; 1-[(4-fluorophenyl)methyl]-N-[1-[2-(4-methoxyphenyl)ethyl]piperidin-4-yl]benzimidazol-2-amine; REGID_for_CID_2247; BSPBio_000212; BSPBio_002684; KBioGR_001686; KBioSS_000928; Astemizole, [O-Methyl-3H]; MLS001148073; DivK1c_000039; SPECTRUM2300094; SPBio_001804; SPBio_002151; BPBio1_000234; GTPL2603; Astemizole, >=98% (HPLC); DTXSID9020110; UPCMLD-DP024:001; BDBM24226; CTK8F7845; HMS500B21; KBio1_000039; KBio2_000928; KBio2_003496; KBio2_006064; KBio3_001904; NINDS_000039; HMS1568K14; HMS1922L12; HMS2090F14; HMS2093L18; HMS2095K14; HMS2234M17; HMS3373B08; HMS3413N12; HMS3677N12; HMS3712K14; Pharmakon1600-02300094; ZINC601274; BCP16088; EX-A3350; Tox21_110680; Tox21_200095; BG0092; CCG-39453; MFCD00153919; NSC329963; NSC759570; STL301859; AKOS005064371; Hestazol, Kelp, Laridal, Retolen, Wareezol, HSBD 6799, BRN 4830190; Tox21_110680_1; API0002918; DB00637; KS-5171; MCULE-9080712110; NSC-329963; NSC-759570; 1-[(4-fluorophenyl)methyl]-N-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidyl]benzimidazol-2-amine; IDI1_000039; QTL1_000010; NCGC00016913-01; NCGC00016913-02; NCGC00016913-03; NCGC00016913-04; NCGC00016913-05; NCGC00016913-06; NCGC00016913-07; NCGC00016913-09; NCGC00016913-10; NCGC00016913-11; NCGC00016913-12; NCGC00016913-14; NCGC00018288-01; NCGC00022520-03; NCGC00022520-04; NCGC00022520-05; NCGC00022520-06; NCGC00022520-07; NCGC00257649-01; HY-12532; K146; LS-32978; SC-18314; ACM1189961394; SBI-0051891.P002; AB00052413; B7409; CS-0011989; FT-0622497; ST51014896; 5318-EP2270008A1; 5318-EP2281815A1; 5318-EP2292617A1; 5318-EP2292619A1; 5318-EP2295409A1; 5318-EP2301933A1; 5318-EP2305640A2; 5318-EP2305659A1; 5318-EP2308562A2; 5318-EP2311827A1; 5318-EP2314590A1; 5318-EP2371811A2; A13899; C06832; D00234; AB00052413-18; AB00052413_19; 844A779; L001015; Q423437; R 43,512; SR-01000003168-2; SR-01000003168-4; BRD-K37249724-001-05-9; BRD-K37249724-001-16-6; Astemizole, United States Pharmacopeia (USP) Reference Standard; 1-(4-fluorobenzyl)-N-(1-(4-methoxyphenethyl)piperidin-4-yl)-1H-benzo[d]imidazol-2-amine; {1-[(4-fluorophenyl)methyl]benzimidazol-2-yl}{1-[2-(4-methoxyphenyl)ethyl](4-p iperidyl)}amine; 1-(4-Fluorobenzyl)-N-(1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl)-1H-benzimidazol-2-amine #; 1-(4-fluorophenylmethyl)-N-{1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl}-1H-benzimidazol-2-amine; 1-[(4-Fluorophenyl)methyl]-N-{1-[2-(4-methoxyphenyl)ethyl]piperidin-4-yl}-1H-benzimidazol-2-amine; 1-[(fluorophenyl)-methyl]-N-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]-1H-benzimidazol-2-amine; 1H-Benzimidazol-2-amine,1-((4-fluorophenyl)methyl)-N-(1-(2-(4-methoxyphenyl)ethyl)-4-piperdinyl); R 42512
Atamestane 1-Methyl-androsta-1,4-diene-3,17-dione; ATAMESTANE; 96301-34-7; Atamestane [INN]; Atamestanum [Latin]; Atamestano [Spanish]; 1-Methylandrosta-1,4-diene-3,17-dione; UNII-62GA3K28B6; CCRIS 6528; SH-489; Androsta-1,4-diene-3,17-dione, 1-methyl-; 62GA3K28B6; 1-methyl-1,4-androstadiene-3,17-dione; Atamestano; Atamestanum; Biomed-777; SCHEMBL59128; CHEMBL2105987; PEPMWUSGRKINHX-TXTPUJOMSA-N; SH489; ZINC4214890; SH 489; DB12194; 1-Methyl-androsta-1,4-diene-3,17-dione; LS-178292; 1-Methyl-androsta-1,4 -diene-3,17-dione; Q4812727; Atamestane; Atamestane
Atenolol 4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]benzeneacetamide; Atenolol; Atehexal
Atorvastatin (betaR,deltaR)-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid; Atorvastatin; (betaR,deltaR)-2-(p-Fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoic acid
Atrazine glutathione conjugate L-gamma-Glutamyl-S-[4-(ethylamino)-6-[(1-methylethyl)amino]-1,3,5-triazin-2-yl]-L-cysteinylglycine; Glycine, N-(S-(4-(ethylamino)-6-((1-methylethyl)amino)-1,3,5-triazin-2-yl)-N-L-gamma-glutamyl-L-cysteinyl)-; NA
Atropine endo(+-)-alpha-(Hydroxymethyl)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester benzeneacetic acid; Atropine; AI3-60219
Auramine O 4,4'-Carbonimidoylbis-N,N-dimethylbenzenamine, Hydrochloride (1:1); Auramine hydrochloride; C.I. 41000
Aureothricin N-(4,5-Dihydro-4-methyl-5-oxo-1,2-dithiolo[4,3-b]pyrrol-6-yl)propanamide; Aureothricin; UNII-0KX00L19Q2
Avermectin B1b 5-O-Demethyl-25-de(1-methylpropyl)-25-(1-methylethyl)avermectin A1a; Avermectin A1a, 5-O-demethyl-25-de(1-methylpropyl)-25-(1-methylethyl)-; Antibiotic C 076B(sub 1b)
Azacitidine 5-Azacytidine; 5-azacytidine; Azacitidine; 320-67-2; Ladakamycin; Azacytidine; Mylosar; Vidaza; 5-azacitidine; Azacitidinum; Azacitidina; Azacitidinum [INN-Latin]; 5-AZAC; Azacitidina [INN-Spanish]; Antibiotic U 18496; NSC-102816; C8H12N4O5; U-18496; 4-Amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one; CCRIS 60; UNII-M801H13NRU; NSC102816; 5AzaC; NSC 102816; HSDB 6879; WR-183027; 5-AZCR; 4-Amino-1-beta-d-ribofuranosyl-1,3,5-triazin-2(1H)-one; EINECS 206-280-2; 5 AZC; U 18496; BRN 0620461; 5-AC; CHEBI:2038; M801H13NRU; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-traizin-2(1H)-one; 4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one; 2-(beta-D-Ribofuranosyl)-4-amino-1,3,5-triazin-2-one; 4-amino-1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,3,5-triazin-2(1H)-one; NCGC00090851-04; NCI-C01569; 5-Azacytidine, 99%; 1,3,5-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl-; DSSTox_CID_116; DSSTox_RID_75378; DSSTox_GSID_20116; mylo sar; Azacitidine [USAN:INN]; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydro-1,3,5-triazin-2-one; SMR000857239; Vidaza (TN); 5-aza-CR; SR-01000075662; Azacitidine (JAN/USAN/INN); Azacitidine [USAN:INN:BAN]; MFCD00006539; NS-17; 1-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-amino-1,3,5-tri azin-2-one; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,3,5-triazin-2-one; CAS-320-67-2; wr 183027; Azacitidine (Vidaza); Antibiotic U18496; U18496; PubChem14167; Spectrum_001262; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazine-2(1H)-one; Spectrum2_000786; Spectrum3_001509; Spectrum4_000922; Spectrum5_001166; MolMap_000062; A 2385; SCHEMBL3741; CHEMBL1489; Lopac0_000035; BSPBio_003157; KBioGR_001444; KBioGR_002556; KBioSS_001742; KBioSS_002565; KSC222S1T; MLS001333121; MLS001333122; MLS002153249; MLS002548894; DivK1c_000125; SPECTRUM1502111; SPBio_000892; EOS113; GTPL6796; DTXSID9020116; BCBcMAP01_000083; CTK1C2919; HMS500G07; KBio1_000125; KBio2_001742; KBio2_002556; KBio2_004310; KBio2_005124; KBio2_006878; KBio2_007692; KBio3_002657; KBio3_003034; NMUSYJAQQFHJEW-KVTDHHQDSA-; 4-amino-1-beta-L-ribofuranosyl-1,3,5-triazin-2(1H)-one; pyrimidine antimetabolite: inhibits nucleic acid replication; cMAP_000082; NINDS_000125; NMUSYJAQQFHJEW-KVTDHHQDSA-N; HMS1921J22; HMS2092D08; HMS2231F15; HMS3259D19; HMS3260G11; Pharmakon1600-01502111; ZINC3861768; 5-Azacytidine, >=98% (HPLC); Tox21_111032; Tox21_302985; Tox21_500035; ABP001093; ANW-27256; BDBM50424715; CCG-39046; EBD145507; NSC758186; s1782; SBB066305; AKOS015896938; Tox21_111032_1; AM83944; API0003444; CS-1287; DB00928; LP00035; LS-1189; MCULE-8318770472; NC00672; NSC-758186; NSC103-627; RTR-013523; SB18981; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triaz; IDI1_000125; 5-azacytidine; Mylosar; Ladakamycin; Vidaza; NCGC00090851-01; NCGC00090851-02; NCGC00090851-03; NCGC00090851-05; NCGC00090851-06; NCGC00090851-07; NCGC00090851-08; NCGC00090851-10; NCGC00178234-01; NCGC00256541-01; NCGC00260720-01; AS-13697; CC-21195; CPD000857239; HY-10586; SAM002264595; SC-09078; SRI-10756_10; SRI-10756_12; ST056940; WR183027; AB2000290; AX8008347; DB-006955; SL-000003; TR-013523; A5777; EU-0100035; FT-0081170; FT-0601307; ST24044344; C11262; D03021; J10124; 33795-EP2275420A1; 33795-EP2295055A2; 33795-EP2295416A2; 33795-EP2298748A2; 33795-EP2298764A1; 33795-EP2298765A1; 33795-EP2305642A2; 33795-EP2311453A1; 33795-EP2311840A1; 124679-EP2270008A1; 124679-EP2292617A1; 124679-EP2295426A1; 124679-EP2295427A1; 320A672; C-14788; Q416451; J-700085; SR-01000075662-1; SR-01000075662-3; SR-01000075662-7; U-18,496; BRD-K03406345-001-02-1; BRD-K03406345-001-27-8; 2-(ss-D-ribofuranosyl)-4-amino-1,3,5-triazin-2-one; s-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl-; Z1522566611; 4-Amino-1-(bet.-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-tr iazin-2(1H)-one; s-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl- (8CI); Azacitidine, United States Pharmacopeia (USP) Reference Standard; 4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; Ladakamycin; Azacitidine, Pharmaceutical Secondary Standard; Certified Reference Material; 4-amino-1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,3,5-triazin-2(1H)-; 5-Azacytidine, Hybri-Max(TM), gamma-irradiated, lyophilized powder, BioXtra, suitable for hybridoma; 5AE; InChI=1/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1; Azacitidine; U 18496
Azelaic acid 4-02-00-02055 (Beilstein Handbook Reference)